Alzheimer's disease

Purpose of Study:  To evaluate the efficacy and safety of an investigational drug taken twice daily in adults with mild to moderate Alzheimer's disease compared to placebo.

Inclusion Criteria:

• Age 55+
• Diagnosed with probable Alzheimer's disease
• Must be able to read, understand and speak English
• CT or MRI 12 months prior to screening
• Must have reliable caregiver

Exclusion Criteria:

• Dementias other than Alzheimer's disease
• History or evidence of any other CNS disorder (stroke, hemorrhage, epilepsy, Parkinson's, etc.)
• Hypothyroidism, folic acid deficiency, or vitamin B12 deficiency
• Patients who have to drive during the study
• History of more than 1 myocardial infarction within 5 years before study entry
• Severe hypotension or hypertension requiring treatment unless controlled for at least 3 months
• History of major depressive episodes such as schizophrenia or bipolar affective disorder
• History or presence of gastro-intestinal, hepatic, or renal disease
• History or presence of cancer (excluding carcinoma in situ)
• Treatment with memory/cognitive enhancing drugs within 2 weeks before screening
• Frequent smoker (more than 10 cigarettes/day), frequent consumer of caffeine (more than 6 cups of tea/coffee per day)
• Pregnant or lactating women
• History of drug or alcohol abuse

If you qualify, all study related care is provided at no charge including:

• Study visits and study related procedures/tests
• Laboratory tests
• Study drug
• Possible reimbursement for time and travel

Inclusion/Exclusion Criteria Must Be Met